Karin Wåhlander

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery
    K Wahlander
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
    Thromb Haemost 87:580-5. 2002
  2. ncbi request reprint Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis
    Karin Wåhlander
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
    Thromb Res 107:93-9. 2002
  3. ncbi request reprint No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor
    Karin Wåhlander
    Experimental Medicine, AstraZeneca R and D, Molndal, Sweden
    Clin Pharmacokinet 42:755-64. 2003
  4. ncbi request reprint Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model
    Karin Wåhlander
    AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Thromb Haemost 95:447-53. 2006
  5. ncbi request reprint Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism
    Karin Wåhlander
    AstraZeneca Research and Development Mölndal, Molndal, Sweden
    Br J Haematol 133:68-77. 2006
  6. ncbi request reprint Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men
    Susanne Johansson
    AstraZeneca R and D Molndal, Molndal, Sweden
    Blood Coagul Fibrinolysis 14:677-84. 2003
  7. ncbi request reprint Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran
    Henry Eriksson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Thromb Haemost 94:522-7. 2005
  8. ncbi request reprint Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis
    Marie Cullberg
    Clinical Pharmacology and Clinical Cardiovascular, AstraZeneca R and D Molndal, Molndal, Sweden
    Clin Pharmacol Ther 77:279-90. 2005
  9. doi request reprint Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837
    Kajs Marie Schützer
    Clinical Development, AstraZeneca R and D Molndal, 431 83 Mölndal, Sweden
    Eur J Clin Pharmacol 66:903-10. 2010
  10. ncbi request reprint A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays
    Stefan C Carlsson
    AstraZeneca R and D Molndal, Molndal, Sweden
    Thromb Res 115:9-18. 2005

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery
    K Wahlander
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
    Thromb Haemost 87:580-5. 2002
    ..03 and p = 0.05, respectively). However, since 90% of the patients with these genetic risk factors will not suffer a VTE event, a general pre-operative genotyping is, in our opinion, of questionable value...
  2. ncbi request reprint Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis
    Karin Wåhlander
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
    Thromb Res 107:93-9. 2002
    ..This study evaluated the pharmacokinetics, pharmacodynamics, and clinical effects of melagatran, the active form of ximelagatran, in patients with both deep vein thrombosis (DVT) and pulmonary embolism (PE)...
  3. ncbi request reprint No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor
    Karin Wåhlander
    Experimental Medicine, AstraZeneca R and D, Molndal, Sweden
    Clin Pharmacokinet 42:755-64. 2003
    ..Objective: To investigate the influence of mild-to-moderate hepatic impairment on the pharmacokinetic and pharmacodynamic properties of ximelagatran...
  4. ncbi request reprint Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model
    Karin Wåhlander
    AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Thromb Haemost 95:447-53. 2006
    ..4; P=0.0010). Both drug combinations were well tolerated. Oral ximelagatran plus ASA has a greater antithrombotic effect in this human ex vivo thrombosis model and a less pronounced prolongation of bleeding time than clopidogrel plus ASA...
  5. ncbi request reprint Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism
    Karin Wåhlander
    AstraZeneca Research and Development Mölndal, Molndal, Sweden
    Br J Haematol 133:68-77. 2006
    ..There was no clear evidence for a higher risk of recurrent VTE or bleeding across subgroups according to the potential prothrombotic factors analysed in this study...
  6. ncbi request reprint Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men
    Susanne Johansson
    AstraZeneca R and D Molndal, Molndal, Sweden
    Blood Coagul Fibrinolysis 14:677-84. 2003
    ..Only moderate increases in capillary bleeding time were observed with s.c. doses up to 5 mg melagatran. Melagatran was well tolerated after s.c. injection, with good local tolerability at the injection site...
  7. ncbi request reprint Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran
    Henry Eriksson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Thromb Haemost 94:522-7. 2005
    ..Long-term use of oral ximelagatran, without coagulation monitoring or dose adjustment, should be feasible and well tolerated in a wide cross-section of patients for the secondary prevention of VTE...
  8. ncbi request reprint Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis
    Marie Cullberg
    Clinical Pharmacology and Clinical Cardiovascular, AstraZeneca R and D Molndal, Molndal, Sweden
    Clin Pharmacol Ther 77:279-90. 2005
    ....
  9. doi request reprint Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837
    Kajs Marie Schützer
    Clinical Development, AstraZeneca R and D Molndal, 431 83 Mölndal, Sweden
    Eur J Clin Pharmacol 66:903-10. 2010
    ..The aim of this study was to evaluate whether the increase in s-creatinine is due to a decrease in renal glomerular filtration rate (GFR) or an inhibition of the tubular secretion of creatinine...
  10. ncbi request reprint A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays
    Stefan C Carlsson
    AstraZeneca R and D Molndal, Molndal, Sweden
    Thromb Res 115:9-18. 2005
  11. ncbi request reprint Trousseau's syndrome - what is the evidence? A population-based autopsy study
    Mats Ogren
    Department of Vascular Surgery, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Thromb Haemost 95:541-5. 2006
    ..001). We conclude that the risk of PE in cancer patients depends not only on the cancer site and spread but also on the histological type. The excess independent risk in pancreatic cancer is intriguing and should warrant further research...
  12. ncbi request reprint No effect of encapsulation on the pharmacokinetics of warfarin
    Susanne Johansson
    Experimental Medicine, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Biopharm Drug Dispos 26:121-7. 2005
    ....